A pivotal phase III trial of edasalonexent in ambulatory patients with Duchenne Muscular Dystrophy regardless of mutation type
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Edasalonexent (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- 04 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018, according to a Catabasis Pharmaceuticals media release.
- 30 Nov 2016 New trial record
- 17 Nov 2016 According to a Catabasis Pharmaceuticals media release, this trial is anticipated to initiate in the second half of 2017.